ArticleGlobal medical genetics2025
Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring
Article in Global medical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Prognostic Significance ofCurrent oncology (Toronto, Ont.) · 2026Article
- Article
- Evaluation of gefitinib alone or combined with bevacizumab in patients withTranslational lung cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the prognostic factors for the treatment efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC) patients with Methods: The study enrolled patients with advanced Results: According to the study of a cohort of 120 patients, we found that more metastatic organs (≥3 organs), specific metastatic patterns (liver and bone involvement), concurrent TP53 mutations, and worse Eastern Cooperative Oncology Group Performance Status (ECOG PS) were associated with shorter PFS. And ECOG PS was an independent predictive factor for PFS. Similarly, metastatic organs ≥ 3 (HR, 2.719; 95 % CI, 1.386-5.333; p = 0.004), ECOG PS of 2 (HR, 10.756; 95 % CI, 4.002-28.906; p < 0.001), and body mass index (BMI)＞24 kg/m Conclusions: This study identified several factors significantly associated with worse response to EGFR-TKIs in NSCLC patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.